Original Research Article
Year: 2020 | Month: December | Volume: 7 | Issue: 12 | Pages: 217-221
Effect of Vildagliptin on Cardiac and Endothelial Function as Compared to Metformin in Type 2 Diabetes Mellitus Patients with Cardiomyopathy
K. M. Dubey
Consultant Physician and Diabetologist, Chapra, Saran, Bihar, India
ABSTRACT
AIM: The main objective of the study was to evaluate the effect of vildagliptin on cardiac and endothelial function as compared to metformin in type 2 diabetes mellitus patients with cardiomyopathy.
Materials and Methods: This was a retrospective study which was conducted at a tertiary out patients department clinic at Chapra district in Bihar. One group of patients received vildagliptin 50 mg BID along with other oral therapy and insulin but were not on metformin. While other group received metformin 1000 to 2000 mg OD or BID along with other oral therapies and insulin but were not on vildagliptin. Demographic data were collected by using predesigned proforma in Microsoft excel sheet and electrocardiographic data at baseline and 1 year follow up were also documented.
Result: It has been found that patients who were on vildagliptin group were having much improved echocardiographic values as compare to the patients who were on metformin based treatment. Both systolic and diastolic blood pressure were well controlled in vildagliptin group ( 132.5±3.2 to 124.3±3.6 mmHg and 86.2±2.8 to 78.3±2.9 mmHg, respectively) as compare to metformin group (138.2±6.1 to 133.1±5.7 and 88.4±3.2 to 83.5±4.1 respectively)(p=0.005). Ejection fraction (EF) were significantly improved in vildagliptin based group (from 65.8±2% to 69.8±1.7%) as compare to metformin based group( from 64.3±2.9% to 65.4±1.7%)(p=0.005).
Conclusion: This retrospective observation demonstrated in patients treated with a dipeptidyl peptidase-4 inhibitor over 12 months, a significant improvements in endothelial diastolic and LV systolic function, as compared to the patients treated with metformin over 12 months.
Keywords: Diabetes Mellitus, Cardiac function, Metformin, Dipeptidyl peptidase-4 inhibitor.
[PDF Full Text]